Restructuring Edition: Even big pharma companies are not immune from workforce reductions. BMS and Sanofi joined that ranks of Evotec, CureVac and BenevolentAI in cutting jobs. Also, Vaxxinity will de-list and Hepion winds down its NASH trial, among other strategic updates.

The former Bayer research head needs to turn the AI-based company around, but investors are skeptical about its attempts to serve big pharma and develop its own pipeline simultaneously.

With all signs pointing towards a year ripe with partnering opportunities, four big pharma dealmakers reveal what they are looking for.

To Jerome Pesenti, the biggest hurdle to integrating generative artificial intelligence into the biopharma industry is accepting that data often knows better than humans.